

# Colon Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C28F485BBE4EN.html>

Date: June 2020

Pages: 1184

Price: US\$ 2,500.00 (Single User License)

ID: C28F485BBE4EN

## Abstracts

Colon Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 53, 8, 206, 30 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 43 and 13 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Colon Cancer - Overview

Colon Cancer - Therapeutics Development

Colon Cancer - Therapeutics Assessment

Colon Cancer - Companies Involved in Therapeutics Development

Colon Cancer - Drug Profiles

Colon Cancer - Dormant Projects

Colon Cancer - Discontinued Products

Colon Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Colon Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),  
H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2),  
H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Colon Cancer - Pipeline by 1ST Biotherapeutics Inc, H1 2020  
Colon Cancer - Pipeline by ABL Bio Inc, H1 2020  
Colon Cancer - Pipeline by ACF Pharmaceuticals LLC, H1 2020  
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2020  
Colon Cancer - Pipeline by Actym Therapeutics Inc, H1 2020  
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020  
Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2020  
Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2020  
Colon Cancer - Pipeline by Adze Biotechnology Inc, H1 2020  
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2020  
Colon Cancer - Pipeline by Trillium Therapeutics Inc, H1 2020  
Colon Cancer - Pipeline by TVAX Biomedical Inc, H1 2020  
Colon Cancer - Pipeline by Tychon Bioscience Inc, H1 2020  
Colon Cancer - Pipeline by Tyg Oncology Ltd, H1 2020  
Colon Cancer - Pipeline by Tyme Technologies Inc, H1 2020  
Colon Cancer - Pipeline by Vault Pharma Inc, H1 2020  
Colon Cancer - Pipeline by Veana Therapeutics LLC, H1 2020  
Colon Cancer - Pipeline by Vernalis R&D Ltd, H1 2020  
Colon Cancer - Pipeline by Viomedix LLC, H1 2020  
Colon Cancer - Pipeline by Viracta Therapeutics Inc, H1 2020  
Colon Cancer - Pipeline by Virogin Biotech Ltd, H1 2020  
Colon Cancer - Pipeline by Well Marker Bio Co Ltd, H1 2020

Colon Cancer - Pipeline by Wellmarker Bio Co Ltd, H1 2020  
Colon Cancer - Pipeline by Westwood Bioscience Inc, H1 2020  
Colon Cancer - Pipeline by WntResearch AB, H1 2020  
Colon Cancer - Pipeline by Wuhan Binhui Biotechnology Co Ltd, H1 2020  
Colon Cancer - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020  
Colon Cancer - Pipeline by XOMA Corp, H1 2020  
Colon Cancer - Pipeline by Y-mAbs Therapeutics Inc, H1 2020  
Colon Cancer - Pipeline by Yuhan Corp, H1 2020  
Colon Cancer - Pipeline by Zenith Epigenetics Ltd, H1 2020  
Colon Cancer - Pipeline by Zovis Pharmaceuticals, H1 2020  
Colon Cancer - Dormant Projects, H1 2020  
Colon Cancer - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Colon Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

1ST Biotherapeutics Inc  
ABL Bio Inc  
ACF Pharmaceuticals LLC  
Actinium Pharmaceuticals Inc  
Actym Therapeutics Inc  
Adgero Biopharmaceuticals Holdings Inc  
Aduro BioTech Inc  
Advanced Cancer Therapeutics LLC  
Adze Biotechnology Inc  
Aeglea BioTherapeutics Inc  
Affimed GmbH  
Agenus Inc  
AGV Discovery SAS  
AIMM Therapeutics BV  
Alfasigma SpA  
Alligator Bioscience AB  
Alpine Immune Sciences Inc  
Amarin Corp Plc  
Ambrx Inc  
Amrita Therapeutics  
ANP Technologies Inc

Aphios Corp  
Apollomics Inc  
AptaBio Therapeutics Inc  
Arbele Ltd  
Ariz Precision Medicine Inc  
Ascelia Pharma AB  
AskAt Inc  
aTyr Pharma Inc  
Aurigene Discovery Technologies Ltd  
Avican Inc  
Avidin Ltd  
Bayer AG  
Baylx Inc  
Beijing Fogangren Bio-Pharm Tech Co Ltd  
BeyondSpring Inc  
Binjiang Pharma, Inc.  
Biogazelle NV  
BioMed Valley Discoveries Inc  
Biomunex Pharmaceuticals  
Black Diamond Therapeutics Inc  
Bliss Biopharmaceutical (Hangzhou) Co Ltd  
Blueprint Medicines Corp  
Boehringer Ingelheim International GmbH  
Bold Therapeutics Inc  
Calidi Biotherapeutics Inc  
Can-Fite BioPharma Ltd  
Cancer Prevention Pharmaceuticals Inc  
Cancure Ltd  
Canget BioTekpharma LLC  
CARsgen Therapeutics Ltd  
Celldex Therapeutics Inc  
Collective BioTherapy Inc  
Celprogen Inc  
CG Oncology Inc  
ChemoCentryx Inc  
Chipscreen Biosciences Ltd  
Clover Biopharmaceuticals  
CMG Pharmaceutical Co Ltd  
Codiak BioSciences Inc



Convert Pharmaceuticals SA  
CStone Pharmaceuticals Co Ltd  
Cureport Inc  
CV6 Therapeutics (Ni) Ltd  
Cytocom Inc  
Cytodyn Inc  
CytomX Therapeutics Inc  
CZ BioMed Corp  
DEKK-TEC Inc  
Diazon Pharmaceuticals Inc  
DiNonA Inc  
Disulfican Ltd  
Diverse Biotech Inc  
Domainex Ltd  
Dracen Pharmaceuticals Inc  
Eli Lilly and Co  
Emcure Pharmaceuticals Ltd  
EncuraGen Inc  
Enochian Biosciences Inc  
EntreChem SL  
EnzymeBioSystems  
Epigene Therapeutics Inc  
Ervaxx Ltd  
Etubics Corp  
Evelo Biosciences Inc  
Evestra Inc  
Evotec SE  
F-star Biotechnology Ltd  
Felicitex Therapeutics Inc  
For-Robin Inc  
Fujifilm Holdings Corp  
Fusion Antibodies Plc  
G1 Therapeutics Inc  
GeoVax Labs Inc  
GlaxoSmithKline Plc  
GlycaNova AS  
GlycoMimetics Inc  
GlycoNex Inc  
GlyTR Therapeutics Inc

GO Therapeutics Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
Hamlet Pharma AB  
HengRui YuanZheng Bio-Technology Co Ltd  
Hibiskus Biopharma Inc  
HitGen LTD  
Horizon Therapeutics Plc  
Huabo Biopharm Co Ltd  
Hummingbird Bioscience Pte Ltd  
I-Mab Biopharma Co Ltd  
i2 Pharmaceuticals Inc  
Ikena Oncology Inc  
Ildong Pharmaceutical Co Ltd  
ImCheck Therapeutics SAS  
Immix BioPharma Inc  
Immune Modulation Inc  
Immunicum AB  
ImmunityBio Inc  
Immunos Therapeutics AG  
Immunotope Inc  
IMPACT Therapeutics Inc  
Infinity Pharmaceuticals Inc  
Inmune Bio Inc  
Innate Pharma SA  
Innopharmax Inc  
Intensity Therapeutics Inc  
InteRNA Technologies BV  
iOmx Therapeutics AG  
J-Pharma Co Ltd  
JenKem Technology Co Ltd  
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
JN Biosciences LLC  
JW Pharmaceutical Corp  
Kadmon Corp LLC  
KAHR medical Ltd  
Karyopharm Therapeutics Inc  
Kineta Inc  
Kitov Pharma Ltd

Kolon Life Science Inc  
Kringle Pharma Inc  
Kymab Ltd  
LipoSeuticals Inc  
Lixte Biotechnology Holdings Inc  
MabVax Therapeutics Holdings Inc  
Machavert Pharmaceuticals LLC  
MacroGenics Inc  
Mateon Therapeutics Inc  
MaxiVAX SA  
Medicenna Therapeutics Corp  
Medicon Pharmaceuticals Inc  
Merck & Co Inc  
Merck KGaA  
MicroQuin Ltd  
Midissia Therapeutics Inc  
Millennium Pharmaceuticals Inc  
Multimmune GmbH  
MultiVir Inc  
Nanjing Jinsirui Biotechnology Co Ltd  
NED Biosystems Inc  
Northern Biologics Inc  
Northwest Biotherapeutics Inc  
Novartis AG  
Novita Pharmaceuticals Inc  
Novonco Pharmaceuticals Inc  
Obio Technology (Shanghai) Corp Ltd  
Oceanyx Pharmaceuticals Inc  
Omeros Corp  
Oncocross Co Ltd  
Oncorus Inc  
Oncovir Inc  
Oncoxx Biotech Srl  
Oneness Biotech Co Ltd  
Ono Pharmaceutical Co Ltd  
Orano Med LLC  
Orpheus Therapeutics Inc  
Pacylex Pharmaceuticals Inc  
Patrys Ltd

Pfizer Inc  
PharmAbcine Inc  
PharmaCyte Biotech Inc  
Phenex Pharmaceuticals AG  
Photolitec LLC  
PHusis Therapeutics Inc  
Pionyr Immunotherapeutics Inc  
PNB Vesper Life Science Pvt Ltd  
Primetime Life Sciences LLC  
Protexase Therapeutics Inc  
Provecs Medical GmbH  
Provectus Biopharmaceuticals Inc  
PTC Therapeutics Inc  
Qilu Puget Sound Biotherapeutics Corp  
Qu Biologics Inc  
Resarci Therapeutics LLC  
Resonant Therapeutics Inc  
Rexahn Pharmaceuticals Inc  
Riptide Bioscience Inc  
Rubius Therapeutics Inc  
Sagimet Biosciences  
Sareum Holdings Plc  
Savoy Pharmaceuticals Inc  
Schrodinger LLC  
Scopus BioPharma Inc  
SEEKYO Therapeutics  
Senex Biotechnology  
SetLance srl  
Shanghai Junshi Bioscience Co Ltd  
Shanghai Pharmaceutical Group Co Ltd  
Shaperon Inc  
Shattuck Labs Inc  
Shionogi & Co Ltd  
Shouyao Holding Co Ltd  
Sichuan Huiyang Life Science and Technology Corp  
SideROS  
SignPath Pharma Inc  
Silicon Therapeutics LLC  
Somantix BV

Soricimed Biopharma Inc  
Sorrento Therapeutics Inc  
Sphaera Pharma Pte Ltd  
Spring Bank Pharmaceuticals Inc  
Stcube Inc  
Sun BioPharma Inc  
Suzhou Sinovent Pharmaceuticals Co Ltd  
Suzhou Stainwei Biotech Inc  
Tactical Therapeutics Inc  
Taiho Pharmaceutical Co Ltd  
Takis Srl  
Talapo Therapeutics Inc  
TargaGenix Inc  
Tarus Therapeutics Inc  
TenCure Ltd  
TeneoBio Inc  
TheraBioPhama  
Theralase Technologies Inc  
Theravectys SA  
Tianjin Hengjia Biotechnology Development Co Ltd  
Tiziana Life Sciences Plc  
Toray Industries Inc  
Transcenta Holding Ltd  
Transgene Biotek Ltd  
Transgene SA  
Trillium Therapeutics Inc  
TVAX Biomedical Inc  
Tychon Bioscience Inc  
Tyg Oncology Ltd  
Tyme Technologies Inc  
Vault Pharma Inc  
Veana Therapeutics LLC  
Vernalis R&D Ltd  
Viomedix LLC  
Viracta Therapeutics Inc  
Virogin Biotech Ltd  
Well Marker Bio Co Ltd  
Wellmarker Bio Co Ltd  
Westwood Bioscience Inc

WntResearch AB  
Wuhan Binhui Biotechnology Co Ltd  
Wuhan YZY Biopharma Co Ltd  
XOMA Corp  
Y-mAbs Therapeutics Inc  
Yuhan Corp  
Zenith Epigenetics Ltd  
Zovis Pharmaceuticals

## I would like to order

Product name: Colon Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C28F485BBE4EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C28F485BBE4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970